News by subject: TRI

Immunic, Inc. , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the presentation of data from the company's phase 2 CALLIPER and...

Spineart SA, manufacturer of the BAGUERA®C Cervical Disc Prosthesis, is delighted to announce completion of enrollment in its U.S. IDE trial studying the BAGUERA®C Cervical Disc Prosthesis in patients with single-level cervical disc disease between...

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, is pleased to announce that it has received approval from the UK's Medicines and...

CalciMedica Inc. (CalciMedica or the Company) , a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases,...

Koning Health, a pioneering medical imaging company, is thrilled to announce that it has received regulatory clearance from the Federal Authority for Nuclear Regulation (FANR) in the United Arab Emirates (UAE), marking a significant milestone in the...

BlueWind Medical, Ltd. today announced that Dr. Osvaldo Padron of Florida Urology Partners in Tampa, Florida, has treated the first patient in the RESTORE study, a prospective, multi-center, open label, post market, randomized controlled trial. The...

Head and neck squamous cell carcinoma (HNSCC) is a type of cancer that affects the mucous membranes of the mouth, nose, and throat. HNSCC is typically associated with tobacco exposure, alcohol abuse, and viral infections. The links between human...

The Lupus Research Alliance (LRA) is pleased to announce the recent recipients of the Lupus Mechanisms and Targets Award (LMTA), whose research will investigate molecular pathways or targets that will lead to new or improved therapies for individuals...

Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule RNA splicing modifiers, today...

Highlights: Monepantel displays a superior safety, tolerability to the leading FDA approved drug Relyvrio®Preliminary efficacy data shows a 58% reduction in the rate of disease progression for Cohort 2 (High Dose) using the FDA primary efficacy...

ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR)...

On an Intent-to-Treat Analysis, Co-Primary Symptom Endpoint Met, Statistical Significance (P<0.025)Multiple Secondary Symptom Endpoints Met, Statistical Significance (P<0.025)On an Intent-to-Treat Analysis, Co-Primary Sign Endpoint and...

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced that the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development has...

BioLineRx Ltd. , a commercial stage...

Akeso (9926.HK) announced that the results of a phase II clinical trial for PD-1/CTLA-4 bispecific antibody?cadonilimab?combined with standard treatment (chemotherapy +/- bevacizumab) as first-line treatment for recurrent/metastatic cervical cancer...

ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, announced that the U.S. Food and Drug Administration (FDA) cleared the Company to initiate the Phase I-IIa...

Equitable Breakthroughs in Medicine Development (EQBMED), led by Yale School of Medicine, Morehouse School of Medicine, the Research Centers in Minority Institutions Coordinating Center (RCMI) at Morehouse School of Medicine, and Vanderbilt...

A new scientific study by Reckitt's Lysol Pro Solutions has revealed the risks that can be posed by the everyday objects we carry with us throughout the...

PCRS Network LLC, a leader in clinical research solutions, is proud to announce the launch of Feasibility PROtm, a cutting-edge platform designed to revolutionize clinical trial protocol development, site feasibility, and patient recruitment. By...

Frederick Health, a leading healthcare system headquartered in Frederick County, Maryland, has chosen GenomOncology's Precision Oncology Platform, seamlessly integrated through the industry-leading MEDITECH Expanse Genomics solution, to elevate its...

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announces that its self-developed novel ADC drug targeting Nectin-4 (R&D Code: 9MW2821) has been granted Fast Track Designation (FTD) by the U.S. Food and Drug...

Curadev, a drug discovery and development company, announced today a significant milestone in its development of drugs targeting the immune system to treat cancer. The dosing of patients with advanced sarcoma and Merkel cell carcinoma by intravenous...

Theradaptive, a market leader in targeted regenerative therapeutics, has received full ethics approval from the Bellberry Ethics Committee to commence its OASIS in-human study in Australia for its novel spinal fusion implant OsteoAdapt SP....

NetraMark Holdings Inc. (the "Company" or "NetraMark")  a generative AI software leader in clinical trial analytics, announces that it has signed a fourth contract in a new indication with a large, publicly listed biopharmaceutical company,...

Oxehealth, a global leader in intelligent patient monitoring for behavioural health has announced the appointment of Todd Haedrich as Chief Executive Officer....

AbbVie today announced that the U.S. Food and Drug Administration (FDA)...

Virtual Incision, a cultivate(MD) portfolio company, has been granted marketing authorization of the MIRAtm Surgical System (MIRA) from the FDA. This marks a significant milestone as MIRA becomes the first miniaturized robotic-assisted surgery device...

Study Achieves Primary and all Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight at all Doses as Compared to Placebo Up to 13.1% Placebo-Adjusted Mean Weight Loss (14.7% From Baseline) Observed After 13 Weeks of...

As previously announced, planning is underway with FDA to advance ibezapolstat into international Phase 3 clinical trials for treatment of C. difficile Infection (CDI)As anticipated, an End of Phase 2 Meeting (EOP2) with FDA is now confirmed to occur...

Pelage Pharmaceuticals, a...

BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will present a poster (#M201) outlining the proposed design for a Phase 3b trial of NurOwn® in amyotrophic...

Nuvalent, Inc. , a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough...

Equitable Breakthroughs in Medicine Development (EQBMED), led by Yale School of Medicine, Morehouse School of Medicine, the Research Centers in Minority Institutions Coordinating Center (RCMI) at Morehouse School of Medicine, and Vanderbilt...

Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. announced today that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) approved Kezar's investigational new drug (IND) application for...

Equitable Breakthroughs in Medicine Development (EQBMED), led by Yale School of Medicine, Morehouse School of Medicine, the Research Centers in Minority Institutions Coordinating Center (RCMI) at Morehouse School of Medicine, and Vanderbilt...

Innocan Pharma Corporation ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the latest findings from the Company's pharmacokinetic study of its LPT-CBD platform in rabbits. The...

BioCity Biopharma is pleased to announce the completion of enrollment of all 120 participants in the IgA nephropathy (IgAN) cohort in a randomized, double-blind, placebo-controlled Phase 2 clinical study of the novel, oral endothelin A (ETA)-receptor...

Cadrenal Therapeutics, Inc., , a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain...

NetraMark Holdings Inc. (the "Company" or "NetraMark")  a generative AI software leader in clinical trial analytics, announces the presentation of new...

Hoth Therapeutics, Inc. , a patient-focused biopharmaceutical company, announced today that it has completed bioanalytical method development under its prior agreement with Altasciences and plans to further engage Altasciences to perform a key study...

XYRA LLC, a private biopharmaceutical company committed to developing innovative therapies for cardiac rhythm disorders with high unmet need, is pleased to announce today it has reached agreement with the FDA ("Agency") at a series of End of Phase 2...

TransThera, a clinical-stage biopharmaceutical company dedicated to innovating differentiated drugs globally, today announced the initiation of IND-enabling studies for TT-02332, a potent, selective and highly CNS-penetrating NLRP3 inflammasome...

IceCure Medical Ltd. ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced new data from a...

- Active relapsed or refractory AML patients 65+ years receiving an Iomab-B led Bone Marrow Transplant (BMT) achieved significant improvement in survival at one and two years compared to control arm patients none of whom survived even one year -...

GSK (GlaxoSmithKline Inc.) has submitted a Supplementary New Drug Submission (SNDS) to Health Canada to expand the use of Arexvy, GSK's...

Heart failure stands as a leading cause of mortality worldwide, demanding advanced treatment options. Despite the urgency for more effective treatments, options for severe heart failure remain limited. Cell transplantation therapy has emerged as a...

J INTS BIO announced on the 26th of month that the Phase 1/2 clinical study of its Novel Oral 4th Generation EGFR TKI "JIN-A02" for the treatment of NSCLC has been accepted for poster presentation at the upcoming American Association for Cancer...

Cynata Therapeutics Limited , a clinical-stage biotechnology company specialising in cell therapeutics, has completed initial analysis of wound surface area in the first 16 patients in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers...

Minnesota based Laplace Interventional announced the successful completion of its first-in-human (FIH) procedure with its Laplace Transcatheter Tricuspid Valve Replacement (TTVR) system by Dr. Thomas Waggoner and Dr. George Makdisi from US Heart and...

Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reactionThe US FDA recently...